The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma

Table 2

Retrospective studies.

Authors (reference)	Journal/year	Patients (OS)	Gender (% male)	Age (range)	Quantification indexes
Nair et al. [27]	Clin Positron Imaging/2000	16 (16)	47	15–29	TBR, %TBR
Franzius et al. [28]	Clin Nucl Med/2000	17 (11)	76	5–36	T : NT-ratio
Hawkins et al. [29]	Cancer/2002	33 (18)	67	6–19	SUV, SUV-ratio
Iagaru et al. [30]	Clin Nucl Med/2008	14 (7)	57	18–56	SUV, SUV-ratio
Mahajan et al. [31]	Pediatr Blood Cancer/2008	39 (39)	49	6–20	SUV
Costelloe et al. [32]	J Nucl Med/2009	31 (31)	61	9–65	SUV, TLG, %TLG
Piperkova et al. [33]	Clin Nucl Med/2009	83 (NR)	NR	NR	SUV
Hamada et al. [34]	Ann Nucl Med/2009	11 (11)	64	10–68	SUV, SUV-ratio
Hawkins et al. [35]	Cancer/2009	40 (40)	NR	7–31	SUV, SUV-ratio
Gaston et al. [36]	Skeletal Radiol/2011	31 (19)	42	14–38	SUV, SUV-ratio, MTV, %ID
Kim et al. [11]	Cancer Res Treat/2011	23 (13)	69	3–19	SUV, SUV-ratio
London et al. [37]	Pediatr Radiol/2012	8 (5)	NR	NR	SUV

SUV: standardized uptake value; T: NT-ratio: tumour to nontumour ratio; TBR: tumour-to-background ratio; TLG: total lesion glycolysis; %TBR: percent change in TBR (baseline to posttherapy); %TLG: percent change in TLG (baseline to posttherapy); MTV: metabolic tumour volume; %ID: percent injected dose retained within the lesion; NR: not reported.